Analysts think CAPR stock price could increase by 141%
Dec 04, 2024, 12:26 PM
-16.41%
What does CAPR do
Capricor Therapeutics, based in Beverly Hills, develops biological therapies for serious medical conditions, focusing on CAP-1002 for Duchenne muscular dystrophy in Phase 3 trials. The company also utilizes exosome technology for various therapeutic applications.
9 analysts think CAPR stock price will increase by 140.94%. The current median analyst target is $39.78 compared to a current stock price of $16.51. The lowest analysts target is $25.25 and the highest analyst target is $80.85.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
